Defendant
1 case as defendant.
Accord Healthcare, Inc. is the US subsidiary of Intas Pharmaceuticals, a global pharmaceutical company headquartered in Ahmedabad, India. Accord Healthcare began operating in the US in 2009, with its US headquarters located in Raleigh, North Carolina. The company is a large-scale provider of generic and specialty pharmaceuticals. Its US annual sales were reported as $668 million, as per IQVIA NSP MAT data as of April 2026.
The company develops, manufactures, and distributes a diverse portfolio of generic and specialty pharmaceuticals, including oral solids, topicals, liquids, lyophilized, and complex injectables. Accord Healthcare has a particular focus on vital therapies such as oncology, autoimmune diseases, and biosimilars. Its product pipeline spans multiple therapeutic classes, with offerings like Lenalidomide Capsules, Clomiphene Citrate Tablets, and Dehydrated Alcohol Injection. They maintain R&D operations with over 500 scientists globally and operate FDA-approved manufacturing facilities.
Accord Healthcare's patent litigation posture is primarily defensive, reflecting its role as an operating company in the pharmaceutical sector. The company has been tracked in one case as a defendant and zero cases as a plaintiff in our database. This sole tracked case, Veloxis Pharmaceuticals, Inc. v. Accord Healthcare et al., is being litigated in the Delaware District Court.
Veloxis Pharmaceuticals, Inc. sued Accord Healthcare and Intas for patent infringement. The case was dismissed with prejudice via a consent judgment filed on January 24, 2024, enjoining Accord and Intas from infringement until the expiration of the patents-in-suit.